Drug Trial Radar · NCT07222917
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
222
Actual
Start
Dec 5, 2025
Primary completion
Dec 10, 2026
Study completion Dec 10, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
Conditions
- Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozinDrug
baxdrostat tablet dapagliflozin tablet
Baxdrostat/PlaceboDrug
baxdrostat tablet placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.Time frame: Up to 12 weeks
Locations
55 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Surprise, Arizona
Research Site
Hollywood, Florida
Research Site
Port Charlotte, Florida
Research Site
Port Orange, Florida
Research Site
East Point, Georgia
Research Site
Champaign, Illinois
Research Site
Wichita, Kansas
Research Site
Greenville, North Carolina
Research Site
Jacksonville, North Carolina
Research Site
New Bern, North Carolina
Research Site
Columbus, Ohio
Research Site
Media, Pennsylvania
Research Site
East Providence, Rhode Island
Research Site
Arlington, Texas
Research Site
Pasadena, Texas
Research Site
San Antonio, Texas
Research Site
Woodbridge, Virginia
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
San Nicolás, Argentina
Research Site
Sofia, Bulgaria
Research Site
Yambol, Bulgaria
Research Site
Courtice, Ontario, Canada
Research Site
Etobicoke, Ontario, Canada
Research Site
Stouffville, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Kaohsiung City, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
New Taipei City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Bangkoknoi, Thailand
Research Site
Changwat Sara Buri, Thailand
Research Site
Hat Yai, Thailand
Research Site
Ratchathewi, Thailand
Research Site
Adana, Turkey (Türkiye)
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.